Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009

Articles

• T-cell and natural killer-cell lymphomas An update based on the 2008 WHO classification

  E.S. Jaffe

  https://doi.org/10.4081/hmr.v3i1.521

  Published: June 11, 2009

  221

  PDF: 254

  • PDF

• First line therapy for peripheral T-cell lymphoma

  D. Sibon

  https://doi.org/10.4081/hmr.v3i1.522

  Published: June 11, 2009

  170

  PDF: 1244

  • PDF

• Treatment of natural killer/T-cell lymphoma

  R Liang

  https://doi.org/10.4081/hmr.v3i1.523

  Published: June 11, 2009

  218

  PDF: 1211

  • PDF

• The role of positron emission tomography in T-cell lymphoma and T-cell specific response criteria

  BD Cheson

  https://doi.org/10.4081/hmr.v3i1.524

  Published: June 11, 2009

  221

  PDF: 461

  • PDF

• Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

  M Duvic

  https://doi.org/10.4081/hmr.v3i1.525

  Published: June 11, 2009

  247

  PDF: 321

  • PDF

• Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma

  HM Prince, M Prince

  https://doi.org/10.4081/hmr.v3i1.526

  Published: June 11, 2009

  337

  PDF: 4371

  • PDF

• Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma

  F Foss, R Advani, K Hymes, B Pohlman, E Jacobsen, J McDonnell, A Lerner

  https://doi.org/10.4081/hmr.v3i1.527

  Published: June 11, 2009

  243

  PDF: 335

  • PDF

• Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside

  PP Piccaluga, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Agostinelli, MT Sista, SA Pileri

  https://doi.org/10.4081/hmr.v3i1.528

  Published: June 11, 2009

  216

  PDF: 285

  • PDF

• Angioimmunoblastic T-cell lymphoma: a tumor of follicular helper T cells derivation with clinical and pathological relevance

  P Gaulard, Y-L Huang, C Thielen, L de Leval

  https://doi.org/10.4081/hmr.v3i1.529

  Published: June 11, 2009

  196

  PDF: 871

  • PDF

• Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative

  G Delsol, L Brugières, P Gaulard, E Espinos, L Lamant

  https://doi.org/10.4081/hmr.v3i1.530

  Published: June 11, 2009

  392

  PDF: 814

  • PDF

• Plitidepsin is active in peripheral T-cell lymphoma: a subset analysis from an ongoing multicenter phase II trial

  C Ferme, MV Mateos, S Szyldergemajn, E Zucca, S Extremera, J Briones, G Alessandro, V Ribrag

  https://doi.org/10.4081/hmr.v3i1.531

  Published: June 11, 2009

  196

  PDF: 192

  • PDF

• Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)

  JE Janik, D O’Mahony, TA Waldmann, JC Morris

  https://doi.org/10.4081/hmr.v3i1.532

  Published: June 11, 2009

  338

  PDF: 359

  • PDF

• Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas

  O Shonukan, AH Dantzig, S Kloeker-Rhoades, I Garcia-Ribas

  https://doi.org/10.4081/hmr.v3i1.533

  Published: June 11, 2009

  293

  PDF: 404

  • PDF

• Forodesine

  V Gandhi

  https://doi.org/10.4081/hmr.v3i1.534

  Published: June 11, 2009

  171

  PDF: 310

  • PDF

• Pentostatin in peripheral T-cell lymphomas

  C Dearden

  https://doi.org/10.4081/hmr.v3i1.535

  Published: June 11, 2009

  197

  PDF: 517

  • PDF

• Preclinical evaluation of sorafenib against B- and T-cell lymphoma

  N Schuelper, B Chapuy, T Relander, L Truemper, G Wulf

  https://doi.org/10.4081/hmr.v3i1.536

  Published: June 11, 2009

  190

  PDF: 139

  • PDF

• Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma

  R Advani

  https://doi.org/10.4081/hmr.v3i1.537

  Published: June 11, 2009

  192

  PDF: 117

  • PDF

• M. Santucci Cutaneous T-cell lymphomas: histology

  M Santucci

  https://doi.org/10.4081/hmr.v3i1.538

  Published: June 11, 2009

  147

  PDF: 1496

  • PDF

• Cutaneous T-cell lymphoma, new insights

  MB Wozniak, SM Rodriguez Pinilla, R Villuendas, M Herrera, PL Ortiz, MA Piris

  https://doi.org/10.4081/hmr.v3i1.539

  Published: June 11, 2009

  187

  PDF: 165

  • PDF

• Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma

  YH Kim

  https://doi.org/10.4081/hmr.v3i1.540

  Published: June 11, 2009

  250

  PDF: 448

  • PDF

• Forodesine

  EA Olsen

  https://doi.org/10.4081/hmr.v3i1.541

  Published: June 11, 2009

  156

  PDF: 120

  • PDF

• Gemcitabine

  M Tani, L Alinari, A Broccoli, E Derenzini, M Fina, L Gandolfi, E Marchi, C Pellegrini, V Stefoni, F Venturini, PL Zinzani

  https://doi.org/10.4081/hmr.v3i1.542

  Published: June 11, 2009

  164

  PDF: 178

  • PDF

• Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: an update

  S Pulini, S Rupoli, G Goteri, R Alterini, M Cantonetti, A Fabbri, P Quaglino, N Pimpinelli

  https://doi.org/10.4081/hmr.v3i1.543

  Published: June 11, 2009

  244

  PDF: 370

  • PDF

• Innovative treatments: bexarotene

  M Duvic

  https://doi.org/10.4081/hmr.v3i1.544

  Published: June 11, 2009

  185

  PDF: 320

  • PDF

• Innovative treatments: bortezomib

  PL Zinzani

  https://doi.org/10.4081/hmr.v3i1.545

  Published: June 11, 2009

  164

  PDF: 148

  • PDF

• Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

  C Querfeld, TM Kuzel, J Guitart, ST Rosen

  https://doi.org/10.4081/hmr.v3i1.546

  Published: June 11, 2009

  285

  PDF: 532

  • PDF

• NOTCH1: a therapeutic target for T cell acute lymphoblastic leukemia/lymphoma

  V Tosello, A Ferrando

  https://doi.org/10.4081/hmr.v3i1.547

  Published: June 11, 2009

  140

  PDF: 319

  • PDF

• Pediatric T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma therapy

  A Pession, R Masetti, R Rondelli

  https://doi.org/10.4081/hmr.v3i1.548

  Published: June 11, 2009

  304

  PDF: 284

  • PDF

• T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma: therapy in adults

  M Bonifacio, O Perbellini, G Pizzolo

  https://doi.org/10.4081/hmr.v3i1.549

  Published: June 11, 2009

  227

  PDF: 2366

  • PDF

• Prognostic factors in cutaneous T-cell lymphoma

  R Willemze

  https://doi.org/10.4081/hmr.v3i1.550

  Published: June 11, 2009

  210

  PDF: 1503

  • PDF

• High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma

  P Reimer

  https://doi.org/10.4081/hmr.v3i1.551

  Published: June 11, 2009

  156

  PDF: 328

  • PDF

• Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas

  P Corradini, A Dodero, G Lambertenghi-Deliliers, F Onida

  https://doi.org/10.4081/hmr.v3i1.552

  Published: June 11, 2009

  219

  PDF: 168

  • PDF